Continued RVU120 treatment study for current participants
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already in a RVU120 study and have taken the drug for at least 5 cycles.
- You are currently benefiting from RVU120 and your doctor agrees you should continue.
- You do not have access to any other approved cancer treatment that works for you.
- You agree to use birth control (if needed) as per local rules.
- You sign a consent form to join this rollover study.
- You agree not to donate blood during the study and for 6.5 months after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called VTRU200 for people with certain advanced blood cancers (like AML, MDS, and DLBCL after CAR-T therapy) and some solid tumors. It may help if standard treatments haven't worked.
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.